Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of
patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there
is a need for better endoscopic visualization and the ability for targeted biopsies. Optical
molecular imaging of neoplasia associated biomarkers could form a promising technique to
accommodate this need. It is known that the biomarker c-Met is overexpressed in dysplastic
and neoplastic areas in BE segments versus normal tissue and has proven to be a valid target
for molecular imaging.
Edinburgh Molecular Imaging Ltd (EMI) has developed a fluorescent tracer specifically
targeting c-Met by labeling a small peptide to a fluorescent fluorophore: 'EMI-137'. The
investigators hypothesize that when EMI-137 is administered intravenously, it accumulates in
c-Met expressing high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), enabling
(early) cancer visualization using a newly developed fluorescent fiber-bundle. This
hypothesis will be tested in the current pilot intervention study.